Computationally Designed Tumor-Selective Antibodies & ADCs for Precision Oncology

9Bio Therapeutics is a Canadian biotechnology company focused on the development of next-generation antibody and antibody–drug conjugate (ADC) therapies for solid tumors, with particular emphasis on tumor-selective targeting and microenvironment-responsive biologics. Our core innovation lies in engineering antibodies that discriminate between malignant and healthy tissues based on tumor-specific antigens and physicochemical features of the tumor microenvironment, enabling improved therapeutic index and reduced off-tumor toxicity.

9Bio is developing a proprietary pipeline of conditionally active monoclonal and bispecific antibodies, including tumor-selective anti-PD-L1 and cancer stem cell–targeting ADCs, designed to enhance efficacy in resistant and heterogeneous tumors while sparing normal tissues. Our approach integrates antibody engineering, structural biology–based design, high-throughput static protein modeling using our proprietary computational platform, and advanced molecular dynamics simulations, together with translational tumor biology, to create biologics that are activated preferentially in the tumor niche.

Within a Horizon Europe Mission Cancer consortium, 9Bio seeks to participate as an industrial R&D and translational innovation partner. We are interested in collaborations with academic cancer centers, hospitals, and technology groups working on precision oncology, tumor microenvironment biology, biomarker discovery, advanced in vitro and in vivo models, and clinical translation.

9Bio can contribute:
• Expertise in antibody and ADC engineering, including bispecific formats and conditional (e.g., pH-responsive) binding technologies.
• High-throughput in silico antibody design, static structural modeling, and molecular dynamics–based optimization supported by proprietary platforms and large-scale computing infrastructure.
• Preclinical models and assays for evaluating tumor-selective binding, internalization, and efficacy in relevant tumor microenvironments.
• Industrial perspective on developability, CMC, and early regulatory positioning of biologics.

Our objective is to co-develop innovative, tumor-selective biologic therapies that align with the EU Cancer Mission goals of improving precision treatment, reducing toxicity, and accelerating translation of breakthrough technologies from bench to bedside.